Primary Job Title Chief Strategy Officer Primary Organization 
Hepalink
Location Weston, Connecticut, United States Regions East Coast, New England, Northeastern US Gender Male
LinkedIn View on LinkedIn
Bruce Wendel served as Vice Chairman and Chief Executive Officer of Abraxis BioScience until October 15, 2010, when Abraxis was acquired by Celgene Corporation. He formerly held the position of Executive Vice-President of Corporate Development of Abraxis BioScience. Wendel joined American Pharmaceutical Partners in 2004 as Vice-President of
Corporate Development. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to business and corporate development.
While at Bristol-Myers Squibb, as Vice President, Corporate Development, International Medicines, he led teams that completed several major acquisitions, divestitures and alliances around the world. These transactions included a $225 M divestiture of Bristol’s U.S. diagnostic division as well as the acquisition of three pharmaceutical firms in Argentina, South Korea, and Peru, and a co-promotion alliance with Smithkline Beecham for Avandia.
Before joining APP, he served as Vice-President, Business Development and Licensing for IVAX Corporation, a generic drug manufacturer, where he completed the Company’s acquisition of 3M’s European respiratory business. Previously, Bruce Wendel served in the legal departments of Playtex and Combe. Bruce Wendel earned a Juris Doctorate degree from Georgetown University Law School where he was an editor of Law & Policy in International Business, and a B.S. from Cornell University.
